Working... Menu
Trial record 98 of 99 for:    FEC

Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00772824
Recruitment Status : Completed
First Posted : October 15, 2008
Last Update Posted : July 17, 2018
Information provided by (Responsible Party):
Manoj Pandey, Banaras Hindu University

Brief Summary:
Glutamine, a non essential branched chain amino acid, is most important non toxic nitrogen carrier in body. It participates in variety of physiological functions. It is a major fuel source of enterocytes and is a substrate for gluconeogenesis in kidney, lymphocytes, and monocytes. It is also a nutrient in muscle protein metabolism in response to infection, inflammation and muscle trauma. The significance of glutamine to metabolic homeostasis becomes evident during periods of stress, when it becomes a conditionally essential amino acid. Role of glutamine as protective agent in hepato-biliary dysfunction, in maintaining mucosal integrity of the Gastrointestinal tract following its administration in patient with major bowel surgery as a supplement and part of TPN in critically ill patients and in patients of septicemia, is well established. However the role of glutamine supplementation in reducing or preventing chemotherapeutic agents induced toxicity in cancer patients is controversial.

Condition or disease Intervention/treatment Phase
Breast Cancer Dietary Supplement: Glutamine Dietary Supplement: IV Glutamine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Case Control
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients- A Prospective, Randomised, Single Blind, Three Arm, Phase Four Prevention Trial
Study Start Date : December 2007
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Glutamine

Arm Intervention/treatment
No Intervention: 1
10 patients (30 cycles) of chemotherapy will receive placebo
Active Comparator: 2
Intravenous glutamine
Dietary Supplement: IV Glutamine
50 ml of 20% glutamine IV before chemotherapy

Experimental: 3
Oral Glutamine
Dietary Supplement: Glutamine
2g/kg body weight twice daily in divided doses for 5 days

Primary Outcome Measures :
  1. Reduction in toxicity [ Time Frame: 3 weeks ]

Secondary Outcome Measures :
  1. Serum level of creatinine kinase and LDH [ Time Frame: 3 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patients > 18 years of age
  • Histologically or cytologically proven breast cancer
  • Receiving CEF chemotherapy cycles presently or in the past
  • The patients who will give informed consent to participate in the study
  • Patients must have sufficient organ and marrow function
  • Stage 1 neuropathy, subclinical neuropathy, surgery induced neuropathy

Exclusion Criteria:

  • Pregnancy
  • Clinical/biochemical severe liver failure
  • Clinical/biochemical severe renal dysfunction
  • Refusal to participate in the study
  • Patients who have received prior chemotherapy with paclitaxel.
  • Patients who have neuropathy due to any known systemic or metabolic causes like diabetes, leprosy, nutritional deficiency induced (vit. B12) etc

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00772824

Layout table for location information
Sir Sunder Lal Hospital
Varanasi, UP, India, 221005
Sponsors and Collaborators
Banaras Hindu University
Layout table for investigator information
Principal Investigator: R K Goel, MD Institute of Medical Sciences


Layout table for additonal information
Responsible Party: Manoj Pandey, Professor, Surgical Oncology, Banaras Hindu University Identifier: NCT00772824     History of Changes
Other Study ID Numbers: GLU_07
First Posted: October 15, 2008    Key Record Dates
Last Update Posted: July 17, 2018
Last Verified: July 2018

Keywords provided by Manoj Pandey, Banaras Hindu University:
Breast cancer
FEC chemotherapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases